Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | GRIA1 | P42261 | 6/20 | 0.51 |
| ▸ | CHRND | Q07001 | 5/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.46 |
| ▸ | CHRNG | P07510 | 1/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16509109 | 0.94 | OPRD1 (0.53) | OPRM1OPRD1OPRK1GRIA1 | |
| SCHEMBL16508987 | 0.93 | OPRD1 (0.52) | OPRM1OPRD1OPRK1GRIA1 | |
| SCHEMBL16509112 | 0.92 | GRIA1 (0.52) | OPRM1OPRD1OPRK1GRIA1CHRND | |
| SCHEMBL13519969 | 0.90 | OPRD1 (0.51) | OPRM1OPRD1OPRK1GRIA1 | |
| SCHEMBL13796086 | 0.89 | OPRD1 (0.55) | OPRM1OPRD1OPRK1GRIA1 | |
| SCHEMBL17176392 | 0.86 | OPRD1 (0.57) | OPRM1OPRD1OPRK1 | |
| SCHEMBL16509133 | 0.85 | OPRM1 (0.53) | OPRM1OPRD1OPRK1GRIA1 | |
| SCHEMBL16509070 | 0.85 | PTPN1 (0.51) | OPRM1OPRD1OPRK1GRIA1 | |
| SCHEMBL16509049 | 0.85 | PTPN1 (0.49) | OPRM1OPRD1OPRK1GRIA1 | |
| SCHEMBL16508968 | 0.85 | PSMB5 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301087-A1 | CRF1 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301087-A1 | CRF1 RECEPTOR COMPOUNDS | CRHR1, CRH, CRHR2 | OPRM1 31/4885OPRD1 26/4885OPRK1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.